



## MEDICAL TIPS

### DIABIZ TABLETS

Issue VIII, No. 31, 2023

#### **Renal, cardiovascular, and safety outcomes of adding sodium-glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis**

Zhang Q, et al. *Int. Urol. Nephrol.* 2023: 1-14

- Meta-analysis of 14 randomized controlled trials to understand the effect of adding sodium-glucose cotransporter-2 inhibitors (SGLT2is) to insulin (INS) in type 2 diabetics (n=6120) was conducted.
- Compared with the INS group, the SGLT2i + INS group showed decreased glycosylated hemoglobin values and insulin dosages ( $p < 0.00001$ ).
- SGLT2i + INS group had a reduced urinary albumin/creatinine ratio and uric acid concentration ( $p = 0.030$ ;  $p = 0.001$ , respectively) without reduction in the estimated glomerular filtration rate (eGFR).
- Blood pressure and body weight were also lower in the SGLT2is + INS group ( $P < 0.01$ ).

**Adding SGLT2i to insulin therapy in T2DM patients showed better glucose control and renal outcomes.**

